Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novartis AG announces FDA approval of Xolair (omalizumab) for chronic idiopathic urticaria


Friday, 21 Mar 2014 02:59pm EDT 

Novartis AG:Says the US Food and Drug Administration (FDA) for the treatment of chronic idiopathic urticaria, a form of chronic hives.Xolair is the first medicine approved by the FDA for CIU since H1-antihistamines.